Insider Transactions in Q1 2021 at Brickell Biotech, Inc. (BBI)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 16
2021
|
Andrew D Sklawer President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,000
-6.02%
|
$7,000
$1.14 P/Share
|
|
Mar 16
2021
|
Andrew D Sklawer President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+14.68%
|
-
|
|
Mar 16
2021
|
David R. Mc Avoy Gen Counsel, CCO, & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
8,750
-8.67%
|
$8,750
$1.14 P/Share
|
|
Mar 16
2021
|
David R. Mc Avoy Gen Counsel, CCO, & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+19.86%
|
-
|
|
Mar 16
2021
|
Deepak Chadha Former Chief R&D Officer & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,750
-12.2%
|
$8,750
$1.14 P/Share
|
|
Mar 16
2021
|
Deepak Chadha Former Chief R&D Officer & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+25.85%
|
-
|
|
Mar 16
2021
|
Jose Breton Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,250
-30.58%
|
$5,250
$1.14 P/Share
|
|
Mar 16
2021
|
Jose Breton Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+46.63%
|
-
|
|
Mar 15
2021
|
Robert Busard Brown Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
100,000
+34.85%
|
$100,000
$1.18 P/Share
|
|
Jan 01
2021
|
Reginald L Hardy CHAIRMAN OF THE BOARD |
BUY
Grant, award, or other acquisition
|
Direct |
47,435
+16.03%
|
$0
$0.78 P/Share
|